Health Care • Biotechnology: Pharmaceutical Preparations
$38.91 ▼ -1.58
(-3.90%)
MKT CAP: $4.23B • VOL: 1.21M
52W L $17 52W H $49
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$33
MEDIAN
$44
MEAN
$44
HIGH
$53
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE EWTX TAPE
EWTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $47.08 | $44.75 | 2025-02-14 | $35.41 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $49.03 | $45.91 | 2025-02-06 | $36.58 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $44.36 | $42.80 | 2025-01-29 | $37.35 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $39.69 | — | 2025-01-17 | $38.13 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $34.24 | $36.96 | 2025-01-09 | $34.63 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $46.30 | $40.47 | 2024-12-18 | $33.85 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $37.74 | $39.30 | 2024-12-04 | $36.19 | -4.3% | 48% | C |